December 16, 2022 eCOA Consortium and PRO Consortium Announce Publication of Two Open Access Articles C-Path’s eCOA Consortium and PRO Consortium are pleased to announce the publication of two open access articles in the Jour
June 8, 2022 PRO Consortium Announces Publication of Open Access Article C-Path’s PRO Consortium is pleased to announce that “Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)
C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the PROMIS® Short Form v2.1—Physical Function-Multiple Sclerosis 15a (PROMIS PFMS—15a) C-Path’s Patient-Reported Outcome (PRO) Consortium announced today it has been awarded a U.S. Food and Drug Administratio
C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the Symptoms of Major Depressive Disorder Momentary Assessment (SMDDMA) C-Path’s Patient-Reported Outcome (PRO) Consortium announced that it has been awarded a U.S. Food and Drug Administration (FDA)